Drug Trial Radar · NCT05030428
Study of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular Disease
Last checked: Nov 19, 2026Latest source record: Nov 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
17,004
Actual
Start
Nov 23, 2021
Primary completion
May 10, 2027
Study completion May 10, 2027
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Sep 1, 2021
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 40 years, up to 100 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Study CKJX839B12302 is a pivotal Phase III trial to evaluate the benefits of inclisiran on major adverse cardiovascular (MACE) events in participants with established cardiovascular disease (CVD).
Conditions
- Atherosclerotic Cardiovascular Disease
Interventions
Inclisiran sodium 300 mgDrug
Subcutaneously injected on Day 1, Month 3 (Day 90) and every 6 months thereafter until EOS visit
PlaceboDrug
Subcutaneously injected on Day 1, Month 3 (Day 90) and every 6 months thereafter until EOS visit
Primary outcomes
What the sponsor says the trial is designed to measure.
- Time to First Occurrence of 3P-MACE (3-Point Major Adverse Cardiovascular Events)Time frame: From randomization to total follow-up time (up to 72 months)
Locations
989 sites in 50 countries. Site status is shown where the registry gives one.
UAB St Vincents
Birmingham, Alabama
Eastern Shore Research Institute
Fairhope, Alabama
G and L Research LLC
Foley, Alabama
Alaska Heart and Vascular
Anchorage, Alaska
Mercy Gilbert Medical Center
Gilbert, Arizona
Cardiovascular Associates of Mesa
Mesa, Arizona
Elite Clinical Studies
Phoenix, Arizona
HonorHealth Heart Group Deer Valley
Scottsdale, Arizona
Clinical Research Inst of Arizona
Sun City West, Arizona
Pima Heart And Vascular Clin Rch
Tucson, Arizona
ARcare Center for Clinical Research
Little Rock, Arkansas
Arkansas Clinical Research
Little Rock, Arkansas
Central Cardiology Medical Center
Bakersfield, California
Alliance Clinical
Canoga Park, California
Inland Psychiatric Medical Group
Chino, California
John Muir Physician Network Clinical Research Center
Concord, California
Triallogix
Fullerton, California
Diabetes Lipid Management Center
Huntington Beach, California
University of Calif Irvine Med Cntr
Irvine, California
UC San Diego Health
La Jolla, California
American Institute of Research
Los Angeles, California
Keck Medical Center USC
Los Angeles, California
University of California LA
Los Angeles, California
VA Palo Alto Health Care System
Palo Alto, California
San Diego Veterans Medical Center
San Diego, California
West Coast Research LLC
San Ramon, California
Helping Hands Medical Associates INC
Santa Ana, California
Syrentis Clinical Research
Santa Ana, California
Encompass Clinical Research
Spring Valley, California
Stanford University Medical Center
Stanford, California
Manshadi Heart Institute
Stockton, California
Harbor UCLA Medical Center
Torrance, California
Blue Coast Research Center LLC
Vista, California
Interv Cardiology Med Grp
West Hills, California
Aurora Denver Cardiology Associates
Aurora, Colorado
Rocky Mountain Regional VA Med Ctr
Aurora, Colorado
Bridgeport Hospital
Bridgeport, Connecticut
d-b-a Greenwich Cardio Assoc
Greenwich, Connecticut
Chase Medical Research LLC
Waterbury, Connecticut
Emerson Clinical Research Institute
Washington D.C., District of Columbia
Showing 40 of 989 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.